Tetralogic Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, and developing novel product candidates to treat cancer and infectious diseases. Founded in 2001, the company currently has two clinical-stage product candidates in development: birinapant and suberohydroxamic acid (4-methoxycarbonyl) phenyl ester (SHAPE). The most recent investment in the company was a $47.00M Convertible Note investment on 24 June 2014.
As an investor, it is important to note that Tetralogic Pharmaceuticals operates in the Biotechnology, Health Care, and Pharmaceutical industries, indicating potential for significant impact and growth in these sectors. The company's focus on developing new treatments for cancer and infectious diseases presents opportunities for addressing crucial medical needs.
